Follow
Douglas A Levine MD
Douglas A Levine MD
NYU Langone Health
Verified email at nyumc.org
Title
Cited by
Cited by
Year
Integrated genomic analyses of ovarian carcinoma
Cancer Genome Atlas Research Network
Nature 474 (7353), 609, 2011
58642011
Integrated genomic characterization of endometrial carcinoma
DA Levine
Nature 497 (7447), 67-73, 2013
34102013
Inferring tumour purity and stromal and immune cell admixture from expression data
K Yoshihara, M Shahmoradgoli, E Martínez, R Vegesna, H Kim, ...
Nature communications 4 (1), 1-11, 2013
31742013
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
23762018
Absolute quantification of somatic DNA alterations in human cancer
SL Carter, K Cibulskis, E Helman, A McKenna, H Shen, T Zack, PW Laird, ...
Nature biotechnology 30 (5), 413-421, 2012
15982012
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
15102018
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
14602018
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics
J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ...
Cell 173 (2), 400-416. e11, 2018
13842018
Rethinking ovarian cancer: recommendations for improving outcomes
S Vaughan, JI Coward, RC Bast, A Berchuck, JS Berek, JD Brenton, ...
Nature Reviews Cancer 11 (10), 719-725, 2011
13362011
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
12762018
Evaluating cell lines as tumour models by comparison of genomic profiles
S Domcke, R Sinha, DA Levine, C Sander, N Schultz
Nature communications 4 (1), 1-10, 2013
11982013
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
11672017
Resistance to therapy caused by intragenic deletion in BRCA2
SL Edwards, R Brough, CJ Lord, R Natrajan, R Vatcheva, DA Levine, ...
Nature 451 (7182), 1111-1115, 2008
9492008
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria, RC Bast, V Beral, JS Berek, ...
Nature reviews Cancer 15 (11), 668-679, 2015
8772015
Machine learning identifies stemness features associated with oncogenic dedifferentiation
TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ...
Cell 173 (2), 338-354. e15, 2018
7212018
Network modeling links breast cancer susceptibility and centrosome dysfunction
MA Pujana, JDJ Han, LM Starita, KN Stevens, M Tewari, JS Ahn, ...
Nature genetics 39 (11), 1338-1349, 2007
6982007
Integrated proteogenomic characterization of human high-grade serous ovarian cancer
H Zhang, T Liu, Z Zhang, SH Payne, B Zhang, JE McDermott, JY Zhou, ...
Cell 166 (3), 755-765, 2016
6892016
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
DS Chi, EL Eisenhauer, J Lang, J Huh, L Haddad, NR Abu-Rustum, ...
Gynecologic oncology 103 (2), 559-564, 2006
6632006
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer
KL Bolton, G Chenevix-Trench, C Goh, S Sadetzki, SJ Ramus, BY Karlan, ...
Jama 307 (4), 382-389, 2012
6092012
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
DS Chi, EL Eisenhauer, O Zivanovic, Y Sonoda, NR Abu-Rustum, ...
Gynecologic oncology 114 (1), 26-31, 2009
5962009
The system can't perform the operation now. Try again later.
Articles 1–20